Ask Finn← Discover
HEALTH & WELLNESS

Simple Blood Test May Predict Alzheimer's Risk Up to a Decade in Advance

By Jordan Hayes · Friday, November 20, 2026
Finn's Take· TL;DR
  • Blood test measuring p-tau217 protein can predict Alzheimer's risk 5-10 years ahead with personalized probability estimates based on age and genetics.
  • A 75-year-old with high p-tau217 levels faces 16% five-year risk and 35% ten-year risk of cognitive impairment versus 5% and 12% with low levels.
  • Test not yet ready for routine screening; needs validation in diverse populations and confirmation that early detection actually improves clinical outcomes.
See this from any side — with sources:
Left takeNeutralRight take

A Window Into the Future of Brain Health

Imagine getting a blood test at your annual checkup that tells you — with meaningful precision — how likely you are to develop memory loss or dementia within the next five to ten years. That possibility moved closer to reality this week, as researchers at Mayo Clinic published a landmark study showing that a specific protein in the bloodstream may serve as a powerful early warning system for Alzheimer's disease.

A blood biomarker for Alzheimer's disease may help estimate a cognitively healthy person's risk of developing mild cognitive impairment or dementia over the next five or ten years, according to the new Mayo Clinic study published in JAMA Neurology. The approach combines a blood measure of phosphorylated Tau 217 (p-tau217) — a protein associated with Alzheimer's disease — with a person's age, sex, and genetic risk to estimate their future chances of cognitive decline.

What the Numbers Actually Mean

Researchers analyzed more than 2,100 participants across two studies, all between ages 60 and 90, who had blood measurements, genetic testing, and repeated cognitive assessments over time. The results revealed striking differences in risk depending on a person's p-tau217 level and age — and the numbers are concrete enough to be genuinely useful in a clinical conversation.

For example, a 75-year-old woman who did not carry APOE ε4 — a common genetic risk variant for Alzheimer's disease — had an estimated five-year risk of mild cognitive impairment of 5% with a relatively low p-tau217 level, jumping to 16% with a higher level. Her estimated 10-year risk rose from 12% to 35%. Age amplified the effect dramatically. At the same high p-tau217 level, the five-year risk ranged from just 6% at age 65 to 37% at age 85.

In this large, multicohort study of 2,684 cognitively unimpaired older adults, higher plasma p-tau217 levels were associated with greater risk of progression to cognitive impairment and faster rates of cognitive decline. Model-based estimates for the absolute risk of cognitive decline over five years were meaningfully elevated in the very high p-tau217 group, reaching 38%.

Beyond a Simple Positive or Negative Result

What sets this research apart from earlier Alzheimer's biomarker work is its emphasis on personalized, probabilistic risk — not just a yes-or-no answer. As study first author and Mayo Clinic laboratory medicine and pathology researcher Alicia Algeciras-Schimnich explained, "The goal is to provide a personalized estimate of the risk of developing cognitive impairment that is more meaningful than simply reporting whether a blood test is positive or negative for amyloid pathology."

Using the Mayo Clinic Study of Aging data, researchers estimated the likelihood of developing mild cognitive impairment or dementia within five and ten years, then used the Alzheimer's Disease Neuroimaging Initiative data to confirm the association between higher p-tau217 levels and greater risk of cognitive decline. The blood test also offers a far less invasive and less expensive alternative to PET brain scans, which have traditionally been required to detect Alzheimer's-related changes in the brain.

Promising, But Not Ready for Everyone Yet

The study does not establish that routine blood testing prevents dementia or improves clinical outcomes, and the risk prediction model is not yet ready for routine screening of people without cognitive symptoms. The researchers note that the risk estimates were developed in the Mayo Clinic Study of Aging and will need further study in more diverse populations and with other p-tau217 blood tests.

Ongoing prevention trials, including AHEAD 3-45 and TRAILBLAZER-ALZ 3, are testing whether amyloid-targeting therapies can delay cognitive decline before symptoms appear — and both used blood biomarkers to help identify participants, underscoring the potential role of tests such as p-tau217 in earlier stages of Alzheimer's disease. The science is moving fast. A blood test that can personalize Alzheimer's risk the way cholesterol tests personalize heart disease risk could fundamentally reshape how doctors and patients approach brain health — catching the disease's earliest footprints long before memory starts to fade.

Have a question about this story?
Ask Finn — answers grounded in this article, from any viewpoint.